CurrentBlue Cross Blue Shield - South DakotaPolicy 07.01.41

Pulsed Radiofrequency Ablation

This policy governs coverage and medical-policy stance for pulsed radiofrequency ablation as a treatment for various chronic pain syndromes for members under Blue Cross Blue Shield - South Dakota.

Policy Summary

PayerBlue Cross Blue Shield - South Dakota

PolicyPulsed Radiofrequency Ablation

Policy CodePolicy 07.01.41

Change TypeAnnual review — no material change

Effective DateMay 1, 2008

Next Review DateN/A

Key ActionDocument and verify prior conservative therapies and baseline pain/function scores before considering pulsed radiofrequency ablation.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

InvestigationalStance

Low/very lowEvidence quality

3–6 monthsShort-term benefit

64999CPT reporting

AnnualReview frequency

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria and Policy Stance

inv-01: Investigational / Not Medically Necessary Indications

Pulsed radiofrequency ablation is considered investigational for the following indications because evidence is insufficient to determine effects on net health outcomes.

Investigational Indications List: PRF ablation is investigational for calcaneal spur/heel spur; carpal tunnel syndrome; chronic head and facial pain including persistent idiopathic facial pain (PIFP)/atypical facial pain/sphenopalatine ganglion; coccydynia; complex regional pain syndrome/reflex sympathetic dystrophy; diabetic peripheral neuropathy; discogenic pain; facet joint pain (cervical, lumbar, thoracic); headaches (chronic, cervicogenic, migraine, cluster, tension); inguinal neuralgia; intercostal neuralgia; low back pain; cervical/thoracic/lumbo-sacral radicular syndrome (e.g., dorsal root ganglion); meralgia paresthetica; metacarpal/metatarsal joint pain; Morton's neuroma; myofascial pain syndrome; neck pain; occipital neuralgia; ophthalmic neuralgia; orchialgia; osteoarthritis of hip/chronic hip pain including post-arthroplasty pain; osteoarthritis of knee/chronic knee pain including genicular nerve PRF for OA or post-arthroplasty pain; peripheral neuromas; pelvic pain; piriformis syndrome; plantar fasciitis; post-herpetic neuralgia; pudendal neuralgia; refractory ventricular arrhythmias; sacro-iliac joint pain; shoulder pain (suprascapular nerve); tarsal tunnel syndrome; thoracic pain; trigeminal neuralgia; vulvodynia

List extracted verbatim from policy.

inv-02: General evidence-based coverage considerations

Summary of the policy's evidence-based stance and key considerations:

Evidence summary: PRF has generally low- to very-low-quality evidence across many indications. Some randomized trials and systematic reviews report short-term improvements in pain and function (often up to 3–6 months), but heterogeneity in PRF protocols, targeted nerves, comparators, small sample sizes, and limited long-term follow-up create substantial uncertainty about durable clinical benefit.

Hayes assessments and systematic reviews repeatedly cite low-quality, heterogeneous evidence and call for additional well-designed randomized comparative trials.

inv-03: Knee osteoarthritis

Indication-specific comparative findings for knee osteoarthritis/genicular interventions:

Knee OA findings: Systematic reviews and network meta-analyses pooling RCTs for knee osteoarthritis found that cooled and conventional radiofrequency modalities generally outperform pulsed RF for pain and function through short-term follow-up (up to 6 months); pooled analyses reported similar adverse event rates between RF modalities and controls. Individual RCTs comparing PRF with other treatments report short-term improvements but favor conventional/cooled RFA in ranking analyses.

Pooled evidence (e.g., Wu et al.) favored C-RFA and conventional RFA over pulsed RFA for pain/function in knee OA.

inv-04: Multiple peripheral and spinal pain conditions

Other specific peripheral and spinal indications with limited or very-low-quality evidence:

Limited evidence indications: Hayes and systematic reviews found very low-quality, sparse, or heterogeneous evidence for PRF in postherpetic neuralgia, cervical spinal pain, sacroiliac joint (SIJ)-related low back pain, dorsal root ganglion (DRG)-targeted radicular pain, pudendal neuralgia, coccygodynia, and multiple other peripheral neuralgias; studies are often small, nonrandomized, or lack long-term follow-up, and additional randomized comparative trials are needed to establish efficacy and appropriate patient selection.

Evidence syntheses repeatedly note uncertainty due to small study sizes, heterogeneity of targets and comparators, and short follow-up.

inv-05: RCT evidence and limitations

Randomized trial examples and common limitations observed:

Individual RCT outcomes: Selected RCTs show mixed short-term benefits: e.g., ultrasound-guided tibial nerve PRF and intralesional RFT for heel pain showed similar 1–3 month improvements with differences diminishing by 3 months; PRF vs platelet-rich plasma in knee OA improved pain at 3 months but effects waned by 6 months; PRF for inguinal neuralgia demonstrated pain reduction through ~3 months but variable durability to 6 months. Limitations across trials include small sample sizes, short follow-up, single-blind or unblinded designs, and potential bias.

Double-blind sham-controlled trials exist for select indications but are limited in number and duration.

inv-06: General evidence-based coverage considerations

Conditions under which PRF may be considered (when evidence shows clinical benefit and supporting documentation is available):

General requirements: 1) A diagnosis that correlates with the patient's symptom pattern and the anatomic target/nerve; 2) Documentation that prior conservative therapies were attempted and failed (e.g., medications, physical therapy, injections) unless contraindicated; 3) Baseline, measurable pain and function scores (e.g., VAS/NRS, disease‑specific function measures); 4) When supported by the literature or local practice, a positive diagnostic/prognostic nerve block (e.g., ≥50% pain relief) before ablation on selected targets; 5) Informed consent that discusses limited durability of benefit and heterogeneous evidence base.

Synthesis of systematic reviews, RCTs and observational studies supports requiring objective baseline measures and documentation of conservative care prior to PRF consideration.

inv-07: Interpretation of randomized trial evidence

Interpretation of randomized trial evidence — overall patterns:

Examples from RCTs: Randomized controlled trials demonstrate mixed short-term benefits depending on indication: some trials report clinically meaningful pain and function improvements at 1–3 months, but effects often decline by 3–6 months; trials are limited by small sample sizes, inconsistent blinding, and heterogeneity in PRF parameters and comparators.

See examples such as Wu et al. (heel pain), Makharita et al. (inguinal neuralgia), and other RCTs showing short-term benefit with limited durability.

Pulsed radiofrequency (PRF) ablation is designated investigational for an extensive list of chronic neuropathic and non‑neuropathic pain syndromes because the evidence is insufficient to determine effects on net health outcomes. The policy enumerates multiple specific indications considered investigational including, but not limited to, calcaneal (heel) spur, carpal tunnel syndrome, persistent idiopathic facial pain/sphenopalatine ganglion pain, coccydynia, complex regional pain syndrome, diabetic peripheral neuropathy, discogenic pain, facet joint pain (cervical/lumbar/thoracic), multiple headache types (chronic, cervicogenic, migraine, cluster, tension), inguinal/intercostal neuralgia, low back pain and radicular syndromes (e.g., dorsal root ganglion), meralgia paresthetica, Morton's neuroma, myofascial pain, occipital/ophthalmic/trigeminal neuralgias, orchialgia, osteoarthritis of the hip and knee (including genicular nerve PRF for knee OA and post‑arthroplasty pain), peripheral neuromas, pelvic pain, piriformis syndrome, plantar fasciitis, post‑herpetic neuralgia, pudendal neuralgia, refractory ventricular arrhythmias, sacro‑iliac joint pain, shoulder pain (suprascapular nerve), tarsal tunnel syndrome, thoracic pain, vulvodynia and related conditions.

Hayes Health Technology Assessments and other evidence reviews repeatedly found the overall quality of evidence across many indications to be low to very low, citing heterogeneity in PRF protocols, variability in targeted nerves and comparators, small numbers of comparative studies, and lack of long‑term follow‑up. These assessments explicitly call for additional well‑designed randomized comparative trials to clarify effectiveness and optimal patient selection.

Systematic reviews, randomized trials, and observational series provide a heterogeneous and generally limited evidence base: while some studies report short‑term improvements in pain and function up to about 3–6 months, sample sizes are often small, follow‑up is brief, and reporting is incomplete. The policy notes this limited evidence when considering coverage decisions and emphasizes the need for larger, longer randomized trials to establish durable clinical benefit.

Within the cited document segments there are no explicit absolute procedural exclusions listed; instead, the policy communicates investigational status for a broad set of indications and references Hayes reviews that characterize the evidence as insufficient — effectively identifying those indications as not supported for coverage based on current data.

Restating the coverage stance: PRF ablation is investigational (not medically necessary) for the enumerated chronic pain syndromes listed in the policy text because available evidence does not adequately demonstrate net health benefit for those indications.

The policy highlights several conditions for which evidence quality is characterized as very low (for example, post‑herpetic neuralgia, many dorsal root ganglion applications, and sacro‑iliac joint–related chronic low back pain). For these conditions the document indicates that current data are insufficient to support coverage pending higher‑quality comparative trials.

Throughout the review the evidence is described as limited and heterogeneous: trials use varied PRF parameters, targets, comparators and outcome measures. This heterogeneity reduces confidence in pooled estimates and complicates generalization of results to routine clinical practice.

Although the document identifies many indications as investigational, the excerpted chunks do not contain an explicit separate statement using the phrase “not medically necessary” for each item; rather, investigational findings and calls for additional research are used to justify noncoverage decisions in practice.

Procedure and Billing Codes

Codesmixed

No codes listed

Procedure CPT - recommended reportingCPT

64999

Unlisted procedure, nervous system (used for pulsed radiofrequency treatment per AMA CPT Editorial Panel guidance cited)

Prior Authorization, Documentation, and Billing Guidance

Note

Member Benefit Verification

Verify member benefits and applicable contract language prior to rendering services. Benefit determinations are based on the member's contract in effect at the time of service; exclusions, limitations, or exceptions may apply.

Verify applicable contract language and member benefits before authorization or billing.

Prior Authorization

Prior Approval

Prior approval: Not applicable for this policy. However, documentation and medical necessity review may still be required at claim submission and benefits should be verified.

Policy states prior approval is Not applicable.
Confirm any payer-specific prior authorization processes outside this policy.

Prior Authorization

Prior Authorization — Documentation of Conservative Care and Outcomes

If prior authorization is requested or required by the member's benefit plan, document prior conservative management and outcomes. Include baseline pain scores, functional measures, and details of conservative therapies tried and their outcomes.

Document baseline pain score (e.g., VAS/NRS) and functional outcome measures (e.g., AOFAS, WOMAC).
Document duration and response to conservative therapy (analgesics, physical therapy, injections, nerve blocks).
Document prior procedures, dates, and objective outcome measures showing inadequate response before PRF is considered.

Documentation Required

Conservative Therapy — Expectation Before PRF

Conservative therapy is described as the initial treatment approach and is expected prior to consideration of pulsed radiofrequency. Examples include analgesics, physical therapy, intra-articular injections, peripheral nerve blocks with anesthetic or corticosteroid, orthoses, and activity modification.

Conservative therapies: analgesics, NSAIDs, physical therapy, stretching, orthoses.
Injections: corticosteroid or local anesthetic peripheral nerve or intra-articular injections.
Conservative measures should be documented and typically attempted before PRF.

Documentation Required

Documentation Requirements

No specific documentation requirements are specified within this policy beyond the general recommendation to document conservative care and clinical outcomes; however, when seeking coverage or payment, include diagnostic/prognostic information, failed conservative treatments, and objective outcome measures.

Include diagnostic details, targeted nerve/anatomic site, prior treatment dates and responses, baseline and follow-up pain/function scores.
Policy does not list additional mandated forms or timelines.

Billing Rule

Procedure Coding Requirement

Procedure coding requirement: report pulsed radiofrequency treatment using CPT code 64999 (Unlisted procedure, nervous system) as noted by the AMA CPT Editorial Panel; include appropriate diagnosis and place of service codes per payer guidance.

Use CPT 64999 — Unlisted procedure, nervous system.
Include relevant ICD-10 diagnosis codes and any required modifier or revenue codes per payer instructions.

Background and Context

Background: Pulsed radiofrequency delivers short bursts of radiofrequency current with intermittent quiet phases that allow electrode cooling and aims to keep tissue temperature below neurodestructive thresholds (~42°C). The technique is intended as a neuromodulatory, less‑ablative alternative to continuous thermal radiofrequency, and several FDA‑cleared generators and probes are available.

Definitions and Outcomes

PRF ablation definition — pulsed RF delivery description

Pulse patternDelivered in short bursts (20 ms pulses) twice per second with quiet phases allowing electrode cooling below neurodestructive threshold (~42°C)

Tissue temperatureAverage tissue temperature remains below ~42°C to avoid neurodestruction

GoalNeuromodulation to reduce pain while limiting adjacent thermal tissue injury compared with continuous RFA

Typical procedural effectLimits tissue damage but often yields shorter duration of pain relief compared with continuous thermal RFA

Standard RFA definition — continuous thermal lesioning description

Energy deliveryContinuous thermal energy applied via electrode tip for 90–130 seconds

Tissue temperatureElectrode tip temperatures typically 70–90°C to produce neurodestructive lesions

MechanismThermal neurolysis creating larger, longer-lasting lesions compared with pulsed techniques

Clinical trade-offLonger-term pain relief but greater adjacent thermal tissue injury and constraints on lesion size/shape

Outcomes of interest — pain, function, QOL, medication use, morbidity

PainSymptom reduction in pain intensity (e.g., VAS/NRS)

FunctionImprovements in functional measures or disease-specific scores (e.g., AOFAS, WOMAC)

Quality of lifeChanges in patient-reported QOL measures

Medication useReductions in analgesic or opioid use following treatment

Treatment-related morbidityProcedure-related adverse events and complications (safety profile)

PRF parameter heterogeneity — variation in frequency, pulse width, temperature, time, cannula/tip size

Parameter variabilityFrequency and pulse width vary across studies

Temperature variationTarget/tissue temperatures differ by protocol and device

Duration/timeTreatment time and number of cycles differ between studies

Cannula and tip sizeCannula gauge and active tip length/size vary and affect lesioning/mechanisms

ImplicationHeterogeneity limits comparability and interpretation of pooled efficacy/safety results

Pulsed radiofrequency (PRF) concise definition

DefinitionApplication of radiofrequency current in pulses at lower temperatures intended to modulate nerve function while minimizing thermal tissue damage

PurposeNeuromodulation rather than neurodestruction to reduce risk of adjacent tissue injury

Typical temperature targetMaintains tissue temperature below neurodestructive threshold (~42°C)

Conventional thermal radiofrequency (CRF) definition and comparative note

DefinitionContinuous radiofrequency heating to higher temperatures (commonly 60–90°C) to create thermal neurolysis

Typical parametersCommonly 60–90°C for 60–130 seconds (policy lists typical 70–90°C for 90–130 seconds)

Comparative noteGuideline evidence generally favors conventional thermal RFA for certain facet-mediated pain; provides longer-term pain relief but greater adjacent thermal injury than PRF

PRF reporting guidance reference to AMA CPT Editorial Panel

AMA CPT reporting guidanceThe AMA CPT Editorial Panel has directed that pulsed radiofrequency procedures be reported using the unlisted CPT code 64999

Billing implicationProviders should follow payer guidance when submitting claims for PRF using the unlisted CPT code

Reference contextPolicy cites AMA CPT Editorial Panel decision dated June 2005 regarding code use for PRF

Required Conservative Therapy Before PRF

inv-47: Conservative management described as first-line and typically expected prior to PRF

Conservative management expectations prior to considering PRF:

First-line conservative care: Conservative management is described as first-line and typically expected prior to PRF; examples include analgesics, physical therapy, rest, NSAIDs, orthoses, stretching, and local injections (anesthetic and/or corticosteroid) depending on the condition.

Conservative therapies are described as standard comparators in practice and are generally expected before PRF for many indications.

inv-48: Attempt and document prior conservative therapies unless contraindicated

Requirement to attempt and document prior conservative therapies unless contraindicated:

Document prior conservative therapies: Attempt and document prior conservative therapies (e.g., medications, physical therapy, orthoses, injections) unless contraindicated; documentation should include therapies tried, duration, and outcomes to support consideration of PRF when evidence is limited.

Studies and reviews recommend PRF after failure of conservative management; policy synthesis emphasizes documentation of prior conservative care.

Frequency Limits and Repeat Treatments

Pulsed radiofrequency ablation frequency note — no procedural frequency limits specified in this part

Procedural frequency limitsNo procedural frequency limits for pulsed radiofrequency ablation are specified in this portion of the document

Repeat procedures notedThe document states nerves can regenerate and repeat procedures may be required; studies have performed repeat treatments based on recurrence

Reporting-only noteSeparate reporting guidance (CPT 64999) is included elsewhere but does not impose frequency limits

PRF procedures frequency — not specified in these chunks

Specification statusFrequency of PRF procedures is not specified in these study descriptions or policy excerpts

Clinical practice implicationVariation in study protocols implies no universal procedural frequency standard within cited literature

DocumentationProviders should document indication and clinical response when repeat procedures are considered (per general documentation recommendations)

PRF repeat treatments — repeat treatments performed in studies based on recurrence; no universal limit specified

Repeat treatments in studiesSome trials allowed repeat PRF treatments based on symptom recurrence (e.g., Makharita et al permitted repeat PRF if VAS >30 mm)

No universal limitPolicy and cited studies do not define a universal maximum number or fixed interval for repeat PRF treatments

Clinical implicationRepeat therapy decisions are individualized based on recurrence, clinical response, and provider judgment

Frequency limits placeholder (empty summary)

Summary statusNo frequency limits or summary statement provided in this segment

Ongoing trials noteOngoing and unpublished trials are listed elsewhere and may inform future frequency guidance

Actionable pointCurrent policy segment does not establish numeric frequency thresholds—refer to full policy or payer-specific guidance for limits

PRF reporting guidance only (frequency/reporting reference)

Reporting guidance onlyFrequency section provides reporting guidance reference: use unlisted CPT 64999 to report PRF per AMA CPT Editorial Panel; this is coding/reporting guidance rather than a frequency limit

Coding riskFailure to use the unlisted CPT code may result in incorrect coding and potential claim denial

Where to submit updatesPolicy refers providers to submit new information or technology updates to the Wellmark Medical Policy Analyst (coding/contact guidance located in policy)

Imaging and Guidance During PRF Procedures

Note

No payer-specified imaging requirement

The background and policy do not specify required imaging guidance for PRF procedures.

Note

Imaging guidance commonly used (ultrasound or fluoroscopy)

Studies commonly used ultrasound or fluoroscopy for targeting peripheral nerves or spinal structures, but the policy does not mandate a specific imaging modality.

Ultrasound commonly used in tibial nerve and genicular PRF studies
Fluoroscopy reported for some intralesional or spinal-targeted procedures

Note

Ultrasound or CT guidance used in studies

When imaging was reported in studies, ultrasound or CT guidance was employed for nerve localization in some PRF procedures.

CT-guided pudendal nerve PRF (case series)
Ultrasound-guided tibial nerve PRF in RCTs

Note

Studies report imaging use; no payer imaging mandate

Several cited studies note use of imaging modalities (ultrasound, CT) for guidance in PRF procedures, but no payer imaging requirement is specified in this document segment.

Not Covered / Exclusions

All indications listed in the policy’s investigational section are considered investigational by this coverage statement; see the investigational/not medically necessary list within the COVERAGE CRITERIA for specific conditions.

Refer to the investigational indications list in the COVERAGE CRITERIA. The policy treats those enumerated conditions as investigational and not supported by sufficient evidence for routine coverage.

No standalone explicit list labeled “not covered” appears in these chunks; however, multiple indications are identified as having insufficient or very low‑quality evidence and are treated as investigational — which implies they are not supported for coverage under the policy in the absence of stronger data.

The provided excerpt does not specify explicit procedural exclusions; rather, it summarizes that the evidence across many indications is judged insufficient and that additional well‑designed randomized comparative trials with larger sample sizes and longer follow‑up are needed to clarify safety and efficacy.

Policy Summary

PayerBlue Cross Blue Shield - South Dakota

PolicyPulsed Radiofrequency Ablation

Policy CodePolicy 07.01.41

Change TypeAnnual review — no material change

Effective DateMay 1, 2008

Next Review DateN/A

Key ActionDocument and verify prior conservative therapies and baseline pain/function scores before considering pulsed radiofrequency ablation.

SourceLink

On This Page